Evidence map›Paper›PMID 31516389›Full record

ArticleCancer cell international2019

MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine.

Liu Wensheng, Zhang Bo, Hu Qiangsheng, Xu Wenyan, Ji Shunrong, Xu Jin, Ni Quanxing, Yu Xianjun, Xu Xiaowu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. [MBD1 knockdown inhibits proliferation, migration and angiogenesis of human umbilical vein endothelial cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Liu Wensheng1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.ORCID 0000-0003-4357-1893
Zhang Bo1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.
Hu Qiangsheng1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.
Xu Wenyan1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.
Ji Shunrong1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.
Xu Jin1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.
Ni Quanxing1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.
Yu Xianjun1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.
Xu Xiaowu1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 200032 Shanghai, China.
Fudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethyl-CpG binding domain protein 1 (MBD1), which couples DNA methylation to transcriptional repression, has been implicated in transcriptional regulation, heterochromatin formation, genomic stability, cell cycle progression and development. It has also been proven that MBD1 is involved in tumor development and progression. However, whether MBD1 is involved in tumorigenesis, especially in gallbladder cancer, is totally unknown.

methodsHuman GBC-SD and SGC996 cells were used to perform experiments. Invasion, wound healing and colony formation assays were performed to evaluate cell viability. A CCK-8 assay was performed to assess gallbladder cancer cell viability after gemcitabine treatment. Western blot analysis was used to evaluate changes in protein expression. Human gallbladder cancer tissues and adjacent nontumor tissues were subjected to immunohistochemical staining to detect protein expression.

resultsWe found that MBD1 expression was significantly upregulated in gallbladder cancer tissues compared with that in surrounding normal tissues according to immunohistochemical analysis of 84 surgically resected gallbladder cancer specimens. These data also indicated that higher MBD1 expression was correlated with lymph node metastasis and poor survival in gallbladder cancer patients. Overexpression and deletion in vitro validated MBD1 as a potent oncogene promoting malignant behaviors in gallbladder cancer cells, including invasion, proliferation and migration, as well as epithelial-mesenchymal transition. Studies have demonstrated that epithelial-mesenchymal transition is common in gallbladder cancer, and it is well known that drug resistance and epithelial-mesenchymal transition are very closely correlated. Herein, our data show that targeting MBD1 restored gallbladder cancer cell sensitivity to gemcitabine chemotherapy.

conclusionsTaken together, the results of our study revealed a novel function of MBD1 in gallbladder cancer tumor development and progression through participation in the gallbladder cancer epithelial-mesenchymal transition program, which is involved in resistance to gemcitabine chemotherapy. Thus, MBD1 may be a potential therapeutic target for gallbladder cancer.

Indexed as

Chemotherapeutic resistanceEpithelial–mesenchymal transitionGallbladder cancerMalignant behaviorMethyl-CpG binding domain protein 1

Identifiers

PMID31516389
PMCPMC6734348
OpenAlexW2973016412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.